The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor-fusion protein, for treatment of recurrent/persistent endometrial cancer: GOG-0229N.
Vicky Makker
No relevant relationships to disclose
Virginia L. Filiaci
No relevant relationships to disclose
Lee-may Chen
No relevant relationships to disclose
Christopher Darus
No relevant relationships to disclose
James Erasmus Kendrick
No relevant relationships to disclose
Gregory Sutton
No relevant relationships to disclose
Katherine Moxley
No relevant relationships to disclose
Carol Aghajanian
No relevant relationships to disclose